SEC Form 4 · accession 0001209191-18-010068
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Altshuler
Officer — EVP, Global Research and CSO
Period of report
Feb 12, 2018
Accepted (ET)
Feb 14, 2018 · 5:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Feb 12, 2018 | S | 1,750 | $149.23 | D | 74,652 | D | |
| Common StockF3,F4 | Feb 12, 2018 | S | 1,900 | $150.67 | D | 72,752 | D | |
| Common StockF3,F5 | Feb 12, 2018 | S | 1,953 | $151.40 | D | 70,799 | D | |
| Common StockF3,F6 | Feb 12, 2018 | S | 700 | $153.11 | D | 70,099 | D | |
| Common Stock | Feb 12, 2018 | S | 100 | $153.84 | D | 69,999 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Mr. Altshuler's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $149.23 (range $148.77 to $149.74).
- F3Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $150.67 (range $150.01 to $150.97).
- F5Open market sales reported on this line occurred at a weighted average price of $151.40 (range $151.02 to $151.90).
- F6Open market sales reported on this line occurred at a weighted average price of $153.11 (range $152.71 to $153.59).